ABILIFY ASIMTUFII: payments to doctors
Payments that named ABILIFY ASIMTUFII as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.9M
- Providers
- 22,235
- Transactions
- 95,003
- Average per transaction
- $84
The per-transaction average — $84 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 22,235 providers the average total is $357, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $7,640,486 | 96.3% |
| Lundbeck LLC | $213,367 | 2.7% |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $80,945 | 1.0% |